Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry

St Joseph University sulodexide tinnitus study

Also known as: Sulodexide, SECIST, SULO-TINNITUS, NCT02737670

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 2

Status

Completed

Target Gene

—

Route / Mode

Oral tablet

Confidence

82%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

Lebanon

Population

adult, tinnitus, repurposed-drug, noise-induced

Trial IDs

Mechanism

Completed randomized double-blind Phase 2 trial of oral sulodexide 25 mg twice daily for chronic idiopathic subjective tinnitus.

Indications

Tinnitus

Notes

Corrected from a generic drug row to the completed St Joseph University SECIST tinnitus trial. No commercial tinnitus program sponsor was verified.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, allCompanies, isIndustrySponsored, stage, status, route, indications...

IDs: NCT02737670

Open

Key Events

2014-08-01

SECIST sulodexide tinnitus trial started

2017-08-01

Registry lists study completion date

Clinical Trials (1)

NCT02737670

Data Checks

institution-led-studyhistorical-completed-studyregistry-only-evidencestudy-level-not-standalone-product

Related Programs

PEDMARK by Fennec Pharmaceuticals

Company: Fennec Pharmaceuticals · Small Molecule · Marketed

SENS-401 (Arazasetron) by Sensorion

Company: Sensorion · Small Molecule · Phase 2

AC102 by AudioCure Pharma

Company: AudioCure Pharma · Small Molecule · Phase 2

SPI-1005 by Sound Pharmaceuticals

Company: Sound Pharmaceuticals · Small Molecule · Phase 3

ACOU085 by Acousia Therapeutics

Company: Acousia Therapeutics GmbH · Small Molecule · Phase 2

CIL001 (Paliroden) by Cilcare

Company: Cilcare SAS · Small Molecule · Phase 1/2